Chiesi Farmaceutici acquired Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a Dublin, Ireland-based commercial-stage biopharmaceutical company.
The total transaction value at close was approximately US$1.25 billion in upfront consideration, plus CVRs representing an additional approximately US$225m of potential consideration. The deal was unanimously approved by both Chiesi and Amryt Boards of Directors and is anticipated to close by the end of the first half of 2023, subject to the satisfaction of all closing conditions.
Led by CEO Dr. Joe Wiley, Amryt is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a portfolio of commercial and development assets.
Led by CEO Marco Vecchia, Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
FinSMEs
09/01/2023